Biogen buoyed despite Alzheimer’s drug’s new, more restrictive label

The U.S. Food and Drug Administration has narrowed the scope of applications for Aduhelm, Biogen Inc.’s newly approved drug for Alzheimer’s disease. But paradoxically, some see that as a potential boon for sales.